A phase 1 safety, pharmacokinetic and pharmacodynamic study of AG-024322, an inhibitor of cyclin-dependent kinase 1, 2 and 4, administered intravenously daily for 5 days every 3 weeks to patients with advanced cancer

Trial Profile

A phase 1 safety, pharmacokinetic and pharmacodynamic study of AG-024322, an inhibitor of cyclin-dependent kinase 1, 2 and 4, administered intravenously daily for 5 days every 3 weeks to patients with advanced cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 15 Aug 2007

At a glance

  • Drugs AG 024322 (Primary)
  • Indications Diffuse lymphoma; Follicular lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Aug 2007 Status change from recruiting to discontinued.
    • 03 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top